GRP
IMDX

Global Retirement Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

Global Retirement Partners’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$8 Hold
1
– – ﹤0.01% 4213
2025
Q3 		$3 Hold
1
– – ﹤0.01% 3860
2025
Q2 		$3 Buy
+1
New +$3 ﹤0.01% 3797

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Global Retirement Partners's IMDX Position: Q4 2025 in Review

Global Retirement Partners held its Insight Molecular Diagnostics (IMDX) position steady in Q4 2025 at 1 share worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #4213.

Global Retirement Partners first reported a position in IMDX in Q2 2025 and has held it in 3 quarters since. 35 funds tracked by Wall St. Rank hold IMDX as of Q4 2025.

  • Global Retirement Partners held 1 share of Insight Molecular Diagnostics worth $8 as of Q4 2025.
  • Global Retirement Partners left its Insight Molecular Diagnostics share count unchanged in Q4 2025.
  • Insight Molecular Diagnostics made up ﹤0.01% of Global Retirement Partners's portfolio in Q4 2025, its #4213 holding.
  • Global Retirement Partners first reported a position in Insight Molecular Diagnostics in Q2 2025 and has held it in 3 quarters since.
  • 35 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2025.

Based on Global Retirement Partners's 13F filing for Q4 2025, filed 6 Feb 2026.